A significant association has been observed in cannabidiol-treated patients and its antipsychotic properties. Clinical symptoms have improved through the ability of CBD to inhibit FAAH activity (fatty acid amide hydrolase – anenzyme that breaks down endocannabinoids) and increases anandamide signaling (endocannabinoid we produce naturally). Cannabidiol reduces psychotic symptoms through this gene and its interaction with serotonin 5-HT1A receptors, GPR55 receptors and vanilloid-1 receptors.
Current Pharmaceutical Design conducted a study titled Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness. Endocannabinoid System (ECS) based therapies have potential beneficial effects through exogenous activation of this system through cannabinoids like CBD. Through the ECS the connection with FAAH gene protein inhibitor can be more effective than CB1 receptor in regards to antidepressant actions.
It must be known that depression is a multi-factorial disorder that can manifest with different symptoms with both genetic and environmental causes. The use of cannabidiol on a consistent basis can aid in the reduction of anxiety and reactions to perceived causes that can lead to disorders such as depression. It is also important to address the individualistic holistic treatment for case-specific disorders such as mental illness, to truly find the proper dosage and therapy that will improve the overall quality of life.